Fact-checked by Grok 2 weeks ago

Botulinum toxin

Botulinum toxin is a potent neurotoxin produced by the anaerobic, spore-forming bacterium Clostridium botulinum, recognized as one of the most poisonous biological substances known to science, with a human lethal dose estimated at 1-3 nanograms per kilogram when inhaled.^[1] This toxin causes botulism, a rare but severe paralytic illness that attacks the nervous system, leading to muscle weakness, difficulty breathing, and potentially fatal respiratory failure if untreated, with symptoms typically appearing 12 hours to 3 days after exposure.^[2] Despite its extreme toxicity, purified and highly diluted forms of botulinum toxin have been harnessed for therapeutic and cosmetic applications since the late 1970s, revolutionizing treatments for conditions involving involuntary muscle activity.^[1] There are seven immunologically distinct serotypes of botulinum toxin (A through G), produced under low-oxygen, low-acid conditions in environments like improperly preserved foods, soil, or wounds, though only serotypes A, B, E, and occasionally F are commonly associated with human botulism cases.^[3] The toxin's mechanism involves binding to cholinergic nerve terminals at neuromuscular junctions, where it cleaves soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins, thereby inhibiting the release of acetylcholine and inducing temporary flaccid paralysis of affected muscles.^[1] This precise action underpins its clinical utility, with serotype A formulations—such as onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), and incobotulinumtoxinA (Xeomin)—being the most widely used, alongside serotype B (rimabotulinumtoxinB, or Myobloc).^[3] Medically, botulinum toxin is FDA-approved for managing a range of disorders, including cervical dystonia, blepharospasm, strabismus, chronic migraines, upper and lower limb spasticity, overactive bladder, and severe hyperhidrosis, while off-label applications extend to neuropathic pain and post-stroke recovery.^[1] In aesthetics, it is renowned for reducing dynamic wrinkles, such as glabellar lines, by relaxing facial muscles, with approvals dating back to 2002 for cosmetic use.^[3] Treatment is generally safe when administered by qualified professionals, with mild, transient side effects like injection-site pain or temporary ptosis, though risks include the development of neutralizing antibodies from repeated high-dose exposure and rare iatrogenic botulism from overuse.^[1] Botulism itself is prevented through proper food preservation, wound care, and prompt antitoxin administration, underscoring the toxin's dual role as both a public health threat and a medical breakthrough.^[2]

Biology and Toxin Properties

Producing Organism

Botulinum toxin is produced by the bacterium Clostridium botulinum, a Gram-positive, rod-shaped, strictly anaerobic, spore-forming organism that is motile and typically measures 0.9–1.2 μm in width by 3–6 μm in length.^[4] This bacterium was first identified in 1897 by Belgian microbiologist Émile van Ermengem during an investigation of a botulism outbreak linked to contaminated ham in Ellezelles, Belgium, where he isolated the anaerobic spore-former and demonstrated its role in toxin production.^[5] C. botulinum exists primarily in spore form in the environment, which is highly resistant to heat, desiccation, and chemicals, allowing it to persist without causing infection in healthy individuals.^[6] The natural habitat of C. botulinum includes soils, marine and freshwater sediments, and decaying vegetation across diverse global environments, from temperate to tropical regions.^[7] While ubiquitous, the bacterium rarely causes disease in healthy adults because its spores do not germinate or produce toxin under normal aerobic conditions; instead, toxin formation occurs only when spores germinate in anaerobic, low-acid (pH above 4.6), low-salt, and low-sugar settings, such as improperly preserved canned or vacuum-packed foods.^[2] Different strains of Clostridium botulinum and related clostridial species produce one of seven immunologically distinct serotypes of botulinum neurotoxin, designated A through G (with serotypes A, B, and E being the most frequently associated with human botulism cases, and serotypes C and D primarily affecting animals).^[8]^[9] Toxin production begins with spore germination triggered by favorable anaerobic conditions, during which the vegetative cells multiply and secrete the neurotoxin as a byproduct of their metabolism, typically peaking in neutral to alkaline pH environments around 25–37°C.^[10] This process is particularly hazardous in food preservation scenarios where oxygen is limited and acidification is inadequate, underscoring the importance of proper canning techniques to prevent germination and growth.^[11]

Toxin Serotypes and Structure

Botulinum toxin is produced by Clostridium botulinum as a progenitor toxin complex (PTC) that protects the active neurotoxin during passage through the gastrointestinal tract. The core neurotoxin is a single-chain polypeptide of approximately 150 kDa, which is post-translationally nicked by bacterial proteases into a dichain structure consisting of a light chain (LC) of about 50 kDa and a heavy chain (HC) of about 100 kDa, linked by a disulfide bond. This neurotoxin associates with non-toxic non-hemagglutinin (NTNH) protein and hemagglutinins (HA33, HA17, and HA70) to form the large PTC (L-PTC), which can reach up to 900 kDa in molecular weight for serotype A.^[12]^[13]^[14] Seven immunologically distinct serotypes of botulinum neurotoxin (BoNT/A through BoNT/G) exist, differentiated primarily by antigenic variations in their receptor-binding domains, which confer serotype-specific immunity and limit cross-protection. These serotypes exhibit differences in potency, with BoNT/A being the most potent (LD₅₀ of approximately 0.5-1.0 ng/kg in mice intraperitoneally) and BoNT/E the least among human-relevant types, alongside variations in clinical duration of action—BoNT/A persists longest (3-6 months in therapeutic applications) due to prolonged intracellular persistence, while BoNT/B and BoNT/E act for shorter durations (1-3 months). Such distinctions arise from sequence variations, with serotypes sharing about 30-70% amino acid identity, influencing stability and proteolytic efficiency.^[13]^[15]^[16] The LC functions as a zinc-dependent endoprotease, coordinating a Zn²⁺ ion via a conserved HExxH motif to cleave specific SNARE proteins, while the HC comprises two functional domains: the N-terminal translocation domain (H_N, ~50 kDa) that facilitates endosomal escape and the C-terminal receptor-binding domain (H_C, ~50 kDa) that targets neuronal cell surface receptors like synaptotagmin and gangliosides. Recent advances in structural biology have elucidated the assembly of the full L-PTC; a 2025 cryo-electron microscopy (cryo-EM) study resolved the 14-subunit, 780 kDa L-PTC of BoNT/B at 2.9 Å resolution, revealing a tripod-like architecture where the NTNH nLoop anchors the M-PTC via the central pore of HA70 trimers to the NTNH-BoNT core, stabilizing the complex against gastric degradation. This structure highlights serotype-conserved assembly principles, with HA components forming a protective scaffold around the neurotoxin.^[17]^[18]^[14] Botulinum toxin is heat-labile, with the neurotoxin denaturing rapidly at elevated temperatures, whereas C. botulinum spores are highly heat-resistant and require autoclaving (121°C for 30 minutes) for inactivation. Boiling at 85°C for 5 minutes suffices to destroy 10³ mouse LD₅₀ units of toxin in food matrices, rendering it non-toxic. Potency is quantified in mouse intraperitoneal LD₅₀ units (1 unit ≈ 1-4 pg of pure BoNT/A), with the estimated human lethal dose for type A being approximately 1 ng/kg body weight intravenously, underscoring its extreme toxicity—one of the most potent known biological agents.^[19]^[8]^[20]

Mechanism of Action

Molecular Interactions

Botulinum toxin exerts its effects through a multi-step molecular process that culminates in the inhibition of neurotransmitter release at presynaptic nerve terminals. The toxin, produced as a single-chain holotoxin, is initially nicked by proteases to form a dichain structure consisting of a heavy chain (HC) and a light chain (LC) linked by a disulfide bond, which facilitates receptor binding and subsequent intracellular actions.^[21] The process begins with specific binding mediated by the C-terminal domain of the HC to dual receptors on the presynaptic membrane: polysialogangliosides such as GT1b and GD1a for initial low-affinity interaction, followed by high-affinity binding to protein receptors like synaptic vesicle glycoprotein 2A (SV2A) for serotype A.^[22]^[23] This receptor-mediated binding triggers clathrin-dependent endocytosis, internalizing the toxin into an endosomal compartment at the nerve terminal.^[21] Upon acidification of the endosome (pH ~5.5), the N-terminal domain of the HC undergoes a conformational change to form a translocation pore, allowing the LC to unfold and translocate across the membrane into the cytosol in a pH-dependent manner.^[21] Once in the cytosol, the disulfide bond is reduced, releasing the LC as a functional enzyme. The LC functions as a zinc-dependent (Zn²⁺) endoprotease, selectively cleaving soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins essential for synaptic vesicle fusion. For example, serotype A cleaves SNAP-25 at the Gln¹⁹⁷-Arg¹⁹⁸ peptide bond, performing a residue-specific hydrolysis that truncates the protein and prevents SNARE complex assembly. This enzymatic action is irreversible due to the toxin's high specificity and the lack of cellular mechanisms to rapidly repair cleaved SNAREs.^[21] The cleavage disrupts the SNARE-mediated docking and fusion of synaptic vesicles with the plasma membrane, resulting in an irreversible blockade of acetylcholine release and subsequent flaccid paralysis.^[21]

Physiological Effects

Botulinum toxin primarily targets cholinergic synapses, inhibiting the release of acetylcholine at peripheral nerve terminals. At the neuromuscular junction, this blockade causes flaccid paralysis of skeletal muscles by preventing synaptic vesicle fusion and neurotransmitter exocytosis. In the autonomic nervous system, it disrupts postganglionic cholinergic transmission, leading to inhibition of functions such as sweating in eccrine glands and salivation from salivary glands. Although sensory nerves rely on non-cholinergic neurotransmitters for afferent signaling, the toxin can inhibit the release of neuropeptides from sensory endings, contributing to observed analgesic effects.^[24] The duration of these effects varies by serotype but is generally temporary, driven by mechanisms of nerve recovery. For botulinum toxin type A, paralysis persists for 3 to 6 months, owing to the formation of new axonal sprouts that establish functional synapses until the original terminals regenerate. The toxin's local spread is dose-dependent, typically extending 3 to 4 cm from the injection site, influenced by factors like volume and concentration. This reversibility occurs through nerve regeneration and sprouting, without causing permanent neuronal damage.^[25]^[26] Serotype differences further modulate physiological outcomes. Type B produces a shorter duration of effect compared to type A, often resolving in 2 to 3 months due to differences in intracellular persistence and recovery kinetics. Type F exhibits the fastest onset of action, typically within hours to days, but yields the briefest overall effect, lasting only weeks. At high doses, botulinum toxin risks systemic dissemination via hematogenous or retrograde axonal transport, potentially resulting in widespread cholinergic blockade and descending flaccid paralysis.^[27]^[28]

Role in Disease

Types of Botulism

Botulism manifests in several distinct clinical forms, primarily differentiated by the route of Clostridium botulinum exposure and toxin production. These types include foodborne, infant, wound, iatrogenic, adult intestinal, and inhalational botulism, each presenting unique epidemiological patterns and risk factors.^[29] Foodborne botulism results from ingesting food contaminated with preformed botulinum neurotoxin, often due to improper home canning or preservation of low-acid foods such as vegetables. The incubation period typically ranges from 12 to 72 hours after consumption. This form accounts for a significant portion of cases, frequently linked to serotypes A, B, and E.^[29]^[30] Infant botulism occurs when C. botulinum spores are ingested and colonize the immature gastrointestinal tract of infants, leading to in vivo toxin production. It predominantly affects children under 1 year of age, with a notable risk from contaminated honey, which is why health authorities advise against feeding honey to infants in this age group. In November 2025, an outbreak of 23 suspected or confirmed cases across 13 U.S. states was linked to contaminated powdered infant formula.^[29]^[31]^[32] This type represents the majority of reported cases in the United States. Wound botulism develops when C. botulinum spores contaminate and infect an anaerobic wound, allowing local toxin production within the tissue. It is often associated with deep puncture wounds or those from contaminated substances, such as in cases involving injection drug use. Unlike foodborne botulism, gastrointestinal symptoms are minimal in this form.^[29]^[30] Iatrogenic botulism is a rare occurrence resulting from excessive or inadvertent administration of botulinum toxin during medical or cosmetic procedures, leading to systemic toxin effects; in 2024, 22 cases across 11 U.S. states were reported following injections of counterfeit botulinum toxin. Adult intestinal botulism, also uncommon, mirrors infant botulism but affects adults with underlying gastrointestinal disorders that permit spore colonization and toxin production in the gut.^[29]^[30]^[33] Inhalational botulism arises from the inhalation of aerosolized botulinum toxin, a form that is largely theoretical and not naturally occurring, though it has been documented in rare laboratory accidents and poses a bioterrorism risk.^[29]^[30] Globally, botulism incidence is estimated at approximately 1,000 cases per year, with foodborne cases—predominantly involving serotypes A, B, and E—comprising the majority. In the United States, around 200–300 cases are reported annually across all types, according to CDC surveillance data.^[34]^[30]^[32]

Pathophysiology and Symptoms

Botulinum toxin, produced by Clostridium botulinum and related clostridia, exerts its effects by binding to presynaptic nerve terminals at the neuromuscular junction and autonomic synapses, where it cleaves SNARE proteins essential for synaptic vesicle fusion, thereby irreversibly blocking acetylcholine release.^[30] This inhibition prevents neuromuscular transmission, leading to flaccid paralysis that typically begins in cranial nerves and descends symmetrically to affect limb and respiratory muscles.^[35] The toxin's potency stems from its ability to translocate into the neuronal cytosol via receptor-mediated endocytosis, with effects persisting until new synaptic terminals form.^[30] Clinical manifestations of botulism arise from this cholinergic blockade, starting with cranial neuropathies such as blurred or double vision, ptosis, dysarthria, and dysphagia, often accompanied by dry mouth and autonomic symptoms like constipation.^[8] As the paralysis progresses downward, patients develop symmetric weakness in the neck, arms, trunk, and legs, with prominent bulbar involvement causing difficulty swallowing and speaking; sensory function and mental status remain intact, and fever is absent unless secondary infection occurs.^[29] In severe cases, diaphragmatic and intercostal muscle paralysis leads to respiratory failure, which is the primary cause of mortality if untreated.^[30] Diagnosis relies on clinical presentation and exposure history, supported by laboratory confirmation through detection of botulinum toxin in serum, stool, or wound specimens via mouse bioassay or mouse neutralization assay, which identifies the serotype.^[29] Polymerase chain reaction (PCR) can detect toxin genes in clinical or food samples, while electromyography (EMG) reveals characteristic findings, including reduced compound muscle action potential amplitude with facilitation on high-frequency repetitive stimulation.^[36] Differential diagnosis includes Guillain-Barré syndrome, myasthenia gravis, and stroke, but the descending paralysis pattern and lack of sensory deficits distinguish botulism.^[30] Treatment involves immediate administration of heptavalent botulinum antitoxin (equine-derived), which neutralizes unbound toxin circulating in the blood but does not reverse existing paralysis.^[37] Supportive care is critical, including mechanical ventilation for respiratory failure, close monitoring in an intensive care unit, and management of complications like aspiration pneumonia; antibiotics are used only for wound botulism to treat the underlying infection.^[29] With prompt antitoxin and intensive support, the case-fatality rate has declined to approximately 3-5%.^[30] Prognosis depends on early intervention, with recovery occurring over 2-8 weeks as motor neurons sprout new axon terminals to restore neuromuscular function, though full resolution may take months and some patients experience persistent fatigue or autonomic dysfunction.^[29] Inhalation or injection botulism may have faster onset and potentially shorter recovery compared to foodborne cases, but all forms require prolonged rehabilitation to regain strength.^[30]

Medical and Cosmetic Uses

Neuromuscular Disorders

Botulinum toxin injections are widely used to manage various neuromuscular disorders characterized by abnormal muscle activity, such as spasticity and dystonias, by inducing localized muscle relaxation through inhibition of acetylcholine release at the neuromuscular junction.^[1] This targeted therapy is particularly effective for conditions involving hypertonia and involuntary movements, offering symptom relief without systemic effects when administered properly.^[38] In spasticity, often resulting from upper motor neuron lesions like post-stroke or cerebral palsy, botulinum toxin reduces muscle tone in affected limbs, improving mobility and daily function. For upper limb spasticity in adults, the recommended Botox dose ranges from 75 to 360 units, divided among key muscles such as the biceps, flexor carpi, and flexor digitorum.^[38] Similarly, for lower limb spasticity, doses of 300 to 400 units target muscles like the gastrocnemius and soleus.^[38] In upper motor neuron syndrome, these injections enhance gait and overall function by alleviating hypertonia in specific muscle groups.^[39] For dystonias, botulinum toxin is FDA-approved for treating blepharospasm and strabismus associated with dystonia since 1989, and for cervical dystonia (torticollis), where it effectively reduces involuntary neck muscle contractions and associated pain.^[38] Meta-analyses of randomized trials confirm that a single treatment session improves dystonia severity by 20-40% on scales like the Toronto Western Spasmodic Torticollis Rating Scale, with benefits lasting 3-4 months.^[40] In spasticity, systematic reviews show significant reductions in muscle tone, typically 1-2 points on the Modified Ashworth Scale (equivalent to 30-50% improvement), alongside gains in range of motion.^[41] Recent 2024 consensus guidelines from the American Academy of Physical Medicine and Rehabilitation endorse botulinum toxin as a first-line option for focal limb spasticity within multidisciplinary care, emphasizing its role in combination with physical therapy.^[42] Administration involves local intramuscular injections, often guided by electromyography (EMG) or ultrasound to ensure precise targeting of hyperactive muscles and minimize complications.^[1] This approach allows for repeat treatments every 3-6 months, tailored to individual response and disease progression.^[38]

Pain and Headache Management

Botulinum toxin type A, specifically onabotulinumtoxinA (Botox), serves as an FDA-approved prophylactic treatment for chronic migraine, defined as headaches occurring on at least 15 days per month for more than three months, with at least eight days featuring migraine characteristics. The U.S. Food and Drug Administration granted approval in October 2010 based on evidence from two pivotal Phase III randomized controlled trials, establishing its role in reducing headache frequency and severity in adults.^[43] This indication addresses a significant unmet need for patients with refractory chronic migraine unresponsive to conventional oral prophylactics.^[44] The standard dosing regimen follows the fixed-site, fixed-dose PREEMPT (Phase III Research Evaluating Migraine Prophylaxis Therapy) protocol, involving intramuscular injections of 155 units of onabotulinumtoxinA distributed across 31 sites in seven head and neck muscle areas, administered every 12 weeks.^[45] In the PREEMPT trials, this approach led to a mean reduction of 8.4 headache days per month at week 24, compared to 6.6 days with placebo, with 49% of treated patients achieving at least a 50% decrease in headache days versus 37% in the placebo group.^[46] These results highlight the toxin's prophylactic efficacy, particularly in reducing migraine/probable migraine days and headache-related disability.^[47] The analgesic mechanism of botulinum toxin in pain management involves cleavage of SNAP-25, a SNARE protein essential for vesicular exocytosis, thereby peripherally inhibiting the release of pro-nociceptive neuropeptides such as substance P and calcitonin gene-related peptide (CGRP) from trigeminal and extracranial sensory afferents.^[48] This anti-nociceptive action modulates peripheral sensitization and reduces central pain signaling without primary reliance on muscle relaxation, distinguishing its sensory effects from motor applications.^[49] In neuropathic pain conditions, such as post-herpetic neuralgia and trigeminal neuralgia, randomized controlled trials have demonstrated significant pain relief, with reductions in visual analog scale scores by up to 50% in refractory cases, attributed to similar neurotransmitter blockade.^[50] Recent investigations from 2023 to 2025 reinforce botulinum toxin's utility in refractory chronic migraine, including as a rescue therapy following failure of anti-CGRP monoclonal antibodies, where it achieved sustained reductions in headache days (mean 6-13 days per month) and improved quality of life in over 50% of patients across multiple cycles.^[51] These studies, involving real-world and controlled cohorts, confirm long-term tolerability and efficacy in difficult-to-treat populations, though the toxin remains contraindicated for acute migraine treatment due to lack of evidence for immediate relief.^[52]

Autonomic Disorders

Botulinum toxin has demonstrated efficacy in treating various autonomic disorders characterized by hypersecretory or overactivity conditions, primarily through its inhibition of acetylcholine release at autonomic synapses, thereby reducing glandular secretions and smooth muscle contractions. This application targets conditions where excessive autonomic activity impairs quality of life, such as in neurological diseases. In primary axillary hyperhidrosis, botulinum toxin type A (onabotulinumtoxinA, BOTOX) is FDA-approved for adults with severe symptoms inadequately managed by topical agents, with approval granted in 2004.^[53] The standard regimen involves 50 units per axilla, administered via 10-15 intradermal or subdermal injections of 0.5 mL each, spaced 1-2 cm apart across the hyperhidrotic area. Clinical trials have shown this treatment reduces sweat production by 80-90% in responders, with effects lasting 4-12 months before reinjection is needed. For sialorrhea, particularly excessive drooling associated with Parkinson's disease, incobotulinumtoxinA (Xeomin) is FDA-approved for chronic sialorrhea in adults since 2018.^[54] Injections are typically delivered intraglandularly into the parotid and submandibular glands, with a recommended dose of 100 Units total per treatment session (30 Units per parotid gland and 15 Units per submandibular gland bilaterally).^[54] This approach significantly decreases saliva production, improving symptoms in up to 70% of patients with Parkinson's, and is well-tolerated with minimal systemic effects.^[55] Neurogenic detrusor overactivity, often seen in spinal cord injury patients leading to urinary incontinence, is effectively managed with intravesical botulinum toxin type A injections, FDA-approved for adults in 2011 and extended to pediatrics aged 5 years and older in 2021.^[38] The recommended dose is 200 units diluted in 30 mL saline and instilled cystoscopically into the detrusor muscle, sparing the trigone. This intervention increases the time to incontinence episodes and improves patient-reported outcomes in spinal cord injury cases.^[56] Long-term studies across these indications confirm sustained benefits with repeat injections every 6-12 months, maintaining efficacy for up to several years without significant loss of response or cumulative safety concerns. For instance, in hyperhidrosis and sialorrhea cohorts, patient satisfaction remains high over multiple cycles, while in detrusor overactivity, durability extends beyond one year in spinal cord injury populations.^[57]

Cosmetic Applications

Botulinum toxin type A is widely used in cosmetic applications to temporarily improve the appearance of dynamic facial wrinkles caused by repetitive muscle contractions. By injecting small doses into targeted facial muscles, the toxin inhibits acetylcholine release at the neuromuscular junction, leading to localized muscle relaxation that smooths overlying skin without affecting surrounding areas. This approach is particularly effective for hyperfunctional lines resulting from mimetic muscle activity, such as those formed by frowning or squinting.^[58] The U.S. Food and Drug Administration (FDA) first approved onabotulinumtoxinA (Botox Cosmetic) in 2002 for the temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity, using a total dose of 20 units divided across five injection sites. In 2013, approval expanded to lateral canthal lines (crow's feet), recommending 24 units total (12 units per side, injected at three sites bilaterally into the orbicularis oculi muscle). Further approval in 2017 covered moderate to severe forehead lines due to frontalis muscle activity, with a typical dose of 20 units, often combined with glabellar treatment for up to 40 units total in that area. These treatments collectively require 20 to 64 units depending on the number of areas addressed, with effects generally lasting 3 to 4 months before gradual return of muscle function.^[59]^[60]^[61]^[62] In 2024, the FDA approved letibotulinumtoxinA-wlbg (Letybo) on February 29 for moderate to severe glabellar lines in adults, administered as 20 units across five sites in the corrugator and procerus muscles. This approval was supported by three randomized, double-blind, placebo-controlled trials (BLESS I, II, and III) involving 1,271 patients aged 18 to 75, where 47% to 65% of Letybo-treated participants achieved at least a 2-grade improvement on the Glabellar Line Scale at week 4, compared to 0% to 2% with placebo. Like other formulations, Letybo's effects persist for approximately 3 to 4 months.^[63]^[64] Cosmetic botulinum toxin procedures are among the most common minimally invasive aesthetic treatments in the United States, with approximately 9.5 million performed in 2023 according to data from the American Society of Plastic Surgeons.^[65] These interventions primarily target upper facial dynamic wrinkles to achieve a rejuvenated appearance, with patient satisfaction driven by the non-surgical nature and predictable outcomes. Beyond FDA-approved indications, off-label uses include treatment of neck bands (platysma hypertrophy) and masseter muscle hypertrophy for facial contouring. For masseter hypertrophy, injections of 20 to 50 units per side relax the muscle, reducing jaw width over repeated sessions, as supported by clinical reviews showing aesthetic improvements in lower facial contours. Neck band treatments similarly involve 10 to 20 units per band to soften vertical platysma lines, though outcomes vary by patient anatomy.^[66]

Other Approved Indications

Botulinum toxin type A (onabotulinumtoxinA, marketed as Botox) received U.S. Food and Drug Administration (FDA) approval in December 1989 for the treatment of strabismus, a condition characterized by eye misalignment due to imbalance in extraocular muscle function.^[67] In this application, the toxin is injected directly into the affected extraocular muscles to induce temporary chemodenervation, thereby weakening the overactive muscle and promoting alignment; typical doses range from 1.25 to 25 units per muscle, with adjustments up to 40 units for larger deviations, administered under electromyographic guidance for precision.^[67]^[68] This approval was supported by early clinical trials demonstrating significant reduction in deviation angles, with success rates of 60-80% in achieving satisfactory alignment after one or more injections, though repeated treatments are often needed due to the toxin's temporary effects lasting 2-4 months.^[69] Hemifacial spasm, involving involuntary unilateral contractions of facial muscles due to irritation of the facial nerve, is another FDA-approved indication for onabotulinumtoxinA, encompassed under the 1989 approval for blepharospasm associated with dystonia or seventh cranial nerve disorders.^[67] Injections target affected muscles such as the orbicularis oculi, zygomaticus, and buccinator, using doses of 10-30 units per site to reduce spasm severity and improve quality of life; effects typically onset within 3-7 days and persist for 3-6 months.^[70] Evidence from small randomized controlled trials (RCTs) and systematic reviews supports its efficacy, with objective spasm reduction in 73-98% of patients and minimal complications when low doses are used, emphasizing the need for precise dosing to avoid facial weakness.^[71]^[72] For achalasia, a motility disorder of the esophagus caused by failure of the lower esophageal sphincter to relax, botulinum toxin injection into the sphincter provides symptomatic relief by inhibiting acetylcholine release and reducing hypertonicity, though this remains an off-label use in the United States.^[73] Endoscopic administration of 80-100 units of onabotulinumtoxinA directly into the sphincter quadrants achieves short-term improvement in dysphagia and esophageal emptying in 65-80% of patients, with effects lasting 6-12 months, positioning it as a bridge therapy for those unsuitable for definitive treatments like myotomy.^[74] Small RCTs have established its safety profile, highlighting low-dose precision to minimize risks like transient chest pain, though relapse rates necessitate repeat injections.^[75] Recent regulatory updates include the European Medicines Agency's longstanding approval of onabotulinumtoxinA for pediatric lower limb spasticity associated with cerebral palsy since the 1990s, with ongoing endorsements for its use in children aged 2-17 years to manage dynamic contractures through targeted muscle injections of 2-5 units/kg.^[76] In the U.S., the FDA expanded approval in October 2019 to include lower limb spasticity in pediatric cerebral palsy patients, building on prior indications for upper limb spasticity from June 2019, supported by RCTs showing improved gait and reduced spasticity scores with precise, low-volume dosing.^[77] These approvals underscore the toxin's role in niche neuromuscular applications, where small-scale RCTs demonstrate sustained benefits with careful dose titration to balance efficacy and safety.^[76]

Safety and Adverse Effects

Common Local Reactions

Common local reactions to botulinum toxin injections are typically mild, transient, and confined to the injection site or nearby areas, occurring in a significant proportion of patients across therapeutic and cosmetic applications. Injection-site pain, often resulting from the needle insertion itself, is frequently reported, with incidence rates varying by indication but generally ranging from 2% to 23% in clinical trials for conditions such as chronic migraine and upper limb spasticity.^[78] Bruising and swelling at the injection site are also prevalent, affecting 11% to 25% of patients, particularly in facial areas where superficial blood vessels are more accessible.^[26] In facial treatments, transient ptosis (drooping of the eyelid) or asymmetry may occur due to unintended diffusion of the toxin to adjacent muscles, with reported incidences of 1% to 5% overall and up to 3% specifically in cosmetic glabellar line studies.^[26]^[78] These effects usually resolve within weeks as the toxin's action wanes. Flu-like symptoms, including headache and myalgia, can emerge shortly after injection, with headache rates around 5% in cosmetic trials and myalgia at approximately 3% in migraine prophylaxis studies.^[78] Management of these reactions emphasizes preventive measures and supportive care. Applying ice to the injection site immediately post-procedure can reduce pain, bruising, and swelling, while advising patients to avoid anticoagulants or antiplatelet agents prior to treatment minimizes hematoma risk.^[26] Incidence of local reactions tends to be higher in cosmetic applications compared to therapeutic uses, owing to the delicate facial injection sites and lower doses per site, though overall rates decrease with repeated treatments as patient tolerance improves.^[26]

Systemic and Rare Complications

Iatrogenic botulism represents a serious systemic complication arising from overdose or unintended systemic absorption of botulinum toxin during therapeutic administration, leading to generalized muscle weakness, dysphagia, blurred vision, ptosis, and potentially respiratory failure.^[79] Doses exceeding 1000 units have been associated with such adverse outcomes, as seen in cases involving up to 19,000 units, though cosmetic and therapeutic doses typically range from 30 to 2000 units.^[79] Treatment involves supportive care, including mechanical ventilation in approximately 4.8% of cases, and administration of botulinum antitoxin, which neutralizes circulating toxin in about 20.4% of reported instances but does not reverse already bound toxin effects.^[79] As of 2020, at least 211 cases of iatrogenic botulism had been documented globally, with subsequent outbreaks adding dozens more cases annually, often linked to unlicensed or counterfeit products, and symptoms frequently requiring intensive care.^[79]^[80]^[81]^[82]^[83] Recent outbreaks, such as 38 cases in the UK in 2025 linked to unlicensed injections, underscore the dangers of non-medical or counterfeit products.^[82] Formation of neutralizing antibodies occurs in 1-5% of chronic users of botulinum toxin type A, potentially reducing treatment efficacy and leading to clinical nonresponsiveness after repeated injections.^[84] Incidence varies by indication, with rates as low as 1.2-1.4% in cervical dystonia but up to 5.9% over 3.5 years of therapy, and higher in conditions like blepharospasm (up to 26.7%).^[84] Compared to type B, type A formulations generally exhibit lower immunogenicity, though repeated high-dose exposure increases antibody risk across serotypes.^[85] Unintended spread of the toxin beyond the injection site can produce distant effects, such as dysphagia occurring in up to 19% of patients treated for cervical dystonia with onabotulinumtoxinA.^[86] This regional diffusion to adjacent muscles, including those involved in swallowing, underscores the need for precise dosing and monitoring in high-risk areas like the neck.^[87] Rare complications include anaphylaxis, an immunologically mediated hypersensitivity reaction that can manifest as severe swelling, respiratory compromise, or circulatory instability, though it is exceedingly uncommon and often linked to components like human albumin in formulations.^[88] Cardiovascular effects, such as arrhythmias, have been reported in high-dose scenarios or iatrogenic botulism, particularly when underlying conditions exacerbate autonomic dysfunction, but these remain infrequent and typically resolve with supportive management.^[89] Post-marketing surveillance continues to affirm the long-term safety profile of botulinum toxin therapies, with 2024 phase III data from trials like READY-4 demonstrating sustained tolerability and low rates of serious adverse events after repeated injections for aesthetic and therapeutic uses.^[90] Ongoing monitoring highlights the importance of reporting systemic events to ensure continued risk mitigation.^[90]

Contraindications and Precautions

Botulinum toxin is contraindicated in patients with known hypersensitivity to the toxin or any of its components, as well as in those with infections at the proposed injection site.^[91] For specific indications such as intradetrusor injections, it is also contraindicated in individuals with urinary tract infections or urinary retention with post-void residual volume greater than 200 mL who are not routinely catheterizing.^[91] Active neuromuscular disorders, such as amyotrophic lateral sclerosis (ALS), myasthenia gravis, or Lambert-Eaton syndrome, represent absolute contraindications due to the risk of exacerbating muscle weakness and respiratory compromise.^[1] Relative contraindications include pregnancy, where botulinum toxin may cause fetal harm based on animal reproduction studies, though human data are limited; it should only be used if the potential benefit justifies the risk.^[91] Breastfeeding is also considered a relative contraindication, as it is unknown whether the toxin passes into human milk or affects breastfed infants, necessitating a careful risk-benefit assessment.^[91]^[1] Precautions are advised for elderly patients, who may experience higher rates of urinary tract infections or retention in certain indications like overactive bladder, and for those with swallowing or respiratory disorders, where monitoring for dysphagia or breathing difficulties is essential.^[91] Dose limits are critical to minimize risks; the maximum cumulative dose for adults across indications should not exceed 400 units in a 3-month interval.^[91] Drug interactions potentiate the effects of botulinum toxin; concurrent use with aminoglycoside antibiotics, curare-like neuromuscular blockers, or other muscle relaxants can increase the risk of generalized muscle weakness and should be avoided or closely monitored.^[91] The U.S. Food and Drug Administration issued a black box warning in 2009 for all botulinum toxin products, highlighting the potential for distant spread of toxin effects beyond the injection site, which may lead to symptoms resembling botulism, including life-threatening swallowing and breathing difficulties.^[92]^[91]

History

Early Discovery and Food Safety

In the early 19th century, German physician Justinus Kerner first systematically described the symptoms of botulism, coining the term "sausage poisoning" (Wurstvergiftung) based on outbreaks linked to poorly preserved blood sausages in Württemberg. Kerner documented clinical features such as descending paralysis, dry mouth, blurred vision, and respiratory failure in approximately 150 cases he observed or studied between 1811 and 1822, attributing the illness to a toxin produced in anaerobic conditions during improper meat curing.^[5] The causative agent was identified in 1897 by Belgian bacteriologist Émile van Ermengem, who isolated Clostridium botulinum from smoked ham implicated in an outbreak at a funeral banquet in Ellezelles, Belgium, where three of 34 musicians died from symptoms consistent with botulism. Van Ermengem's microbiological analysis confirmed the bacterium's spore-forming nature and its production of a heat-labile toxin responsible for the paralytic effects, marking the first isolation of the organism and laying the foundation for understanding foodborne transmission.^[5] Botulism outbreaks in the United States during the 1920s, particularly from home-canned vegetables and commercial products like olives, prompted significant advancements in food preservation techniques. These incidents, including a 1919-1920 national crisis affecting dozens, highlighted the inadequacy of boiling-water canning for low-acid foods, leading to the establishment of pressure canning standards by the U.S. Department of Agriculture. The recommended "botulinum cook" process—heating to 121°C for at least 3 minutes—ensures a 12-log reduction in C. botulinum spores, drastically reducing outbreak risks.^[93]^[94] During the 1920s and 1930s, researchers at the University of California, including P. Tessmer Snipe and Hermann Sommer, advanced toxin purification through acid precipitation and adsorption methods, yielding a more concentrated and stable form suitable for further study. Their 1928 work isolated type A toxin with enhanced potency, enabling immunological and physiological investigations that informed early antitoxin development.^[95] Global efforts to mitigate botulism have since focused on acidification of preserved foods (e.g., adding citric acid or vinegar to achieve pH below 4.6) and enhanced surveillance systems, contributing to a marked decline in incidence from thousands of cases annually in the early 20th century to approximately 1,000 cases reported worldwide each year. Organizations like the World Health Organization emphasize these preventive measures alongside education on safe canning, resulting in near-elimination of commercial foodborne outbreaks in developed regions.^[8]

Military and Initial Medical Research

During World War II, the United States, United Kingdom, and Japan pursued separate military research programs on botulinum toxin as a potential biological weapon, focusing on its purification for dissemination via bombs or aerosols. In the US, research began in April 1942 under the War Research Service, with significant efforts at Camp Detrick (now Fort Detrick) in Maryland starting in 1943; scientists including Edward Schantz, Carl Lamanna, and Adolph Abrams worked to purify type A toxin into a crystalline form in 1946, enabling weaponization studies for aerial bombs and cluster munitions filled with toxin-laden cakes or dusts, though stability issues limited practical deployment.^[96] Similarly, the UK initiated studies in October 1940 at Porton Down under Paul Fildes and David Willis Henderson, designating the toxin as "agent X" for aerosol delivery or food contamination sabotage, but production challenges and instability prevented operational use.^[96] Japan's Imperial Army, through Unit 731 in occupied Manchuria, explored biological agents including botulinum toxin as part of its broader biological warfare program from the early 1930s to 1945, though details of specific applications remain limited compared to agents like anthrax.^[97] In the late 1940s, initial medical research emerged alongside military efforts, with Arnold Burgen and colleagues demonstrating the toxin's mechanism of action. In a seminal 1949 study, Burgen's team showed in vitro that botulinum toxin induces neuromuscular blockade by inhibiting acetylcholine release at the neuromuscular junction in isolated rat diaphragms, distinguishing its effects from curare-like blockers and laying the groundwork for understanding its paralytic potential beyond weaponry.^[98] This finding shifted some focus toward therapeutic possibilities, though military priorities dominated. Throughout the 1950s and 1960s, the US Army at Fort Detrick scaled up production of purified type A botulinum toxin under Edward Schantz, who had achieved initial crystallization in 1946 using acid precipitation and ammonium sulfate methods reported in a 1946 Science paper. Schantz's team refined crystallization techniques, enabling mass production of stable, high-purity toxin batches for stockpiling, with estimates indicating the US amassed quantities equivalent to over a billion lethal doses (LD50) by 1949 for potential aerosol or bomb delivery.^[99] These stockpiles, along with other biological agents, were ordered destroyed by President Nixon in 1969 as part of renouncing offensive biological weapons, with final disposal completed in the early 1970s.^[100] The transition to medical applications began in the 1970s through early clinical trials led by ophthalmologist Alan Scott. Motivated by the need for non-surgical options for strabismus, Scott initiated primate studies in 1973 using Schantz's purified type A toxin to induce targeted muscle weakening, reporting initial human injections for strabismus correction that same year with promising results in aligning eye muscles without surgery.^[69] Building on these, Scott secured an Investigational New Drug (IND) approval from the FDA in 1977, allowing formal human trials under the name Oculinum and marking the ethical pivot from bioweapon to therapeutic agent. Post-Cold War, the ethical landscape shifted decisively as declassified military research and Nixon's 1969 ban facilitated repurposing the toxin for medicine, emphasizing its precision in localized paralysis over mass lethality; this transition, accelerated by Scott's work, transformed botulinum toxin from a symbol of biowarfare horror to a regulated pharmaceutical by the 1980s.^[101]

Therapeutic Development and Commercialization

The therapeutic development of botulinum toxin began with its initial U.S. Food and Drug Administration (FDA) approval in 1989 for the treatment of strabismus and blepharospasm associated with dystonia, marketed as Botox by Allergan.^[38] This approval marked the transition from experimental use to a regulated medical product, based on clinical evidence demonstrating its efficacy in relaxing overactive eye muscles.^[102] Subsequent expansions in the early 2000s broadened its clinical applications. In December 2000, the FDA approved Botox for cervical dystonia in adults, addressing abnormal head position and neck pain through targeted muscle relaxation.^[103] This was followed by approval in July 2004 for severe primary axillary hyperhidrosis in adults, enabling treatment of excessive underarm sweating by inhibiting sweat gland activity.^[53] By October 2010, the FDA extended approval to the prophylaxis of chronic migraine in adults, with injections reducing headache frequency in patients experiencing 15 or more headache days per month.^[104] The cosmetic sector drove significant commercialization growth, with FDA approval in April 2002 for Botox Cosmetic to temporarily improve moderate-to-severe glabellar lines in adults.^[59] Prior to this, off-label cosmetic uses had surged in popularity since the late 1990s, fueled by anecdotal reports of wrinkle reduction, which propelled Botox into a household name and prompted Allergan to vigorously protect its trademark against genericization.^[105] Competition emerged as other formulations gained regulatory clearance, diversifying market options. Dysport (abobotulinumtoxinA) was approved in the European Union in 1991 for certain muscle disorders and received U.S. FDA approval in April 2009 for cervical dystonia.^[106] Xeomin (incobotulinumtoxinA) followed with FDA approval in August 2010 for cervical dystonia and blepharospasm.^[107] Later entrants included Jeuveau (prabotulinumtoxinA-xvfs), approved by the FDA in February 2019 for glabellar lines, and Letybo (letibotulinumtoxinA-wlbg), approved in February 2024 for the same indication and launched later that year.^[108]^[64]^[63] Key milestones underscore the toxin's commercial success and expanding scope. Global sales of botulinum toxin products, led by Botox, exceeded $5 billion in 2023, reflecting robust demand in therapeutic and aesthetic markets, with continued growth into 2024.^[109] Pediatric approvals accelerated from 2016 onward, including expansions for upper and lower limb spasticity in patients aged 2 to 17 years by 2019 and 2020, enhancing access for children with conditions like cerebral palsy.^[110]

Society, Regulation, and Production

Brand Names and Economics

Botulinum toxin products are marketed under several major brand names, each utilizing different formulations of the toxin type A. Botox, or onabotulinumtoxinA, is produced by Allergan, an AbbVie company, and has been a leading product since its approval for cosmetic use in 2002. Dysport, known as abobotulinumtoxinA, is manufactured by Ipsen and is approved for both therapeutic and aesthetic indications, offering a formulation with a higher diffusion profile compared to Botox. Xeomin, or incobotulinumtoxinA, from Merz Pharmaceuticals, is distinguished by its "naked" toxin structure without complexing proteins, potentially reducing immunogenicity risks. Letybo, or letibotulinumtoxinA, developed by Hugel Inc., received FDA approval in 2024 for glabellar lines and represents the newest entrant, gaining traction in the U.S. market for its efficacy in aesthetic applications. The U.S. botulinum toxin market reached approximately USD 4.67 billion in 2023, with aesthetic or cosmetic uses accounting for about 80% of the total, while therapeutic applications comprised roughly 20%. This dominance of cosmetics reflects high consumer demand for non-invasive anti-aging treatments, though therapeutic uses continue to grow due to expanding FDA approvals for conditions like chronic migraine and spasticity. The market is projected to expand at a CAGR of 9.8% through 2030, driven by increasing procedure volumes and innovation in formulations. Treatment costs in the U.S. vary by brand and provider but typically range from $10 to $20 per unit, with a standard cosmetic facial treatment requiring 30 to 40 units, resulting in out-of-pocket expenses of $300 to $600. Insurance coverage is generally available for FDA-approved therapeutic indications, such as Medicare reimbursement for spasticity or chronic migraine when deemed medically necessary, covering up to 80% of costs after deductibles; however, cosmetic uses are rarely insured and remain patient-funded. Globally, the botulinum toxin market is experiencing robust growth, particularly in the Asia-Pacific region, where it is forecasted to expand at a CAGR of 14.6% from 2023 to 2031, fueled by rising disposable incomes, medical tourism, and cultural emphasis on aesthetics in countries like South Korea and China. Patent expirations, such as for key Botox formulations expected in 2026, are anticipated to lower barriers for biosimilars and generics, potentially increasing accessibility and market competition while pressuring pricing for established brands.

Regulatory Status and Access

Botulinum toxin products, such as onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport), are regulated by the U.S. Food and Drug Administration (FDA) as prescription biologics and are not classified as controlled substances under the Drug Enforcement Administration (DEA) schedules.^[111] They carry a pregnancy category C designation, indicating that animal studies have shown adverse effects on the fetus, but there are no adequate well-controlled studies in humans, and use during pregnancy should only occur if the potential benefit justifies the risk.^[112] Certain formulations, including Botox, are subject to a Risk Evaluation and Mitigation Strategy (REMS) program to mitigate risks such as distant spread of toxin effects and ensure safe use through provider education and patient monitoring.^[113] In November 2025, the FDA issued warnings to 18 websites selling counterfeit or unapproved versions of Botox and similar products, following reports of severe illnesses, including symptoms of botulism such as muscle weakness and breathing difficulties, linked to these unlicensed sources. Additionally, a multistate outbreak of infant botulism was investigated starting in November 2025, affecting at least 23 infants and linked to contaminated ByHeart infant formula, underscoring ongoing risks from improper production and distribution of botulinum toxin-producing bacteria. These incidents highlight the importance of regulatory enforcement to prevent public health threats from counterfeit or contaminated products.^[114]^[115]^[116] Internationally, the European Medicines Agency (EMA) has authorized multiple botulinum toxin type A products, including Botox for therapeutic indications like cervical dystonia and Nuceiva for glabellar lines, with similar safety and efficacy requirements as the FDA.^[117] Botulinum toxin is included on select national essential medicines lists for specific therapeutic uses, such as focal dystonias in South Africa's list, highlighting its recognized role in managing certain neurological conditions where alternatives are limited.^[118] Access to botulinum toxin treatments remains challenged by high costs, which can exceed thousands of dollars per session, disproportionately affecting low-income individuals and populations in resource-limited settings where insurance or public funding is unavailable.^[119] Off-label applications, common for conditions like migraines or spasticity, are legally permissible in the U.S. but expose providers to potential liability risks if adverse outcomes occur outside approved indications.^[120] In the United States, health insurance coverage favors therapeutic applications; for instance, since FDA approval for axillary hyperhidrosis in 2004, many plans cover up to 100% of costs for eligible patients meeting criteria like prior treatment failures, whereas cosmetic uses for wrinkle reduction are typically excluded as non-medically necessary.^[121]^[122] Coverage variability persists across insurers and states, often requiring documentation of medical necessity. Regulatory controversies have included the rise of direct-to-consumer advertising in the early 2000s, following FDA approval of Botox Cosmetic in 2002, which Allergan pursued through magazines and television to promote its wrinkle-reducing effects, prompting debates over risk communication to non-medical audiences.^[123] In 2008, the FDA issued alerts on serious adverse events, including muscle weakness and breathing difficulties from distant toxin spread, particularly in pediatric off-label uses for cerebral palsy spasticity, leading to label updates and enhanced post-marketing surveillance but no product recall.^[124]

Production Methods and Biosecurity

Botulinum toxin is primarily produced through the anaerobic fermentation of Clostridium botulinum bacteria in specialized bioreactors designed to maintain strict oxygen-free conditions, as the organism is an obligate anaerobe.^[125] This process typically involves culturing strains such as the Hall strain for serotype A, which is widely used in commercial production due to its high toxin yield and stability. Following fermentation, the toxin is extracted from the culture supernatant and purified using techniques such as acid precipitation, filtration, and chromatography, including ion-exchange and size-exclusion methods, to isolate the active neurotoxin from bacterial debris and impurities.^[126] Yields from these processes generally range from 1 to 30 mg of purified toxin per liter of culture, depending on strain optimization and scale.^[127] Commercial formulations of botulinum toxin serotype A differ in their composition, with traditional products containing the 150 kDa core neurotoxin bound to complexing proteins (such as non-toxic non-hemagglutinin and hemagglutinins) forming a larger 900 kDa complex for enhanced stability during storage and delivery.^[128] In contrast, newer "naked" or complexing protein-free formulations, like incobotulinumtoxinA, consist solely of the purified 150 kDa neurotoxin without these accessory proteins, potentially reducing immunogenicity risks associated with bacterial contaminants.^[129] These naked variants are stabilized using excipients such as human serum albumin or sucrose, allowing for equivalent therapeutic efficacy while minimizing the formation of neutralizing antibodies.^[129] Due to its extreme potency and ease of production, botulinum neurotoxin is classified by the Centers for Disease Control and Prevention (CDC) as a Category A bioterrorism agent, posing a high risk for mass casualties through aerosolization, food contamination, or injection.^[130] This designation highlights dual-use concerns, where legitimate medical research and production could be diverted for malicious purposes, a risk amplified after the 2001 anthrax attacks that prompted heightened scrutiny of biological agents.^[131] In response, post-9/11 legislation, including the USA PATRIOT Act of 2001 and the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, established the Federal Select Agent Program to regulate possession, use, and transfer of botulinum neurotoxin.^[132] Handling botulinum neurotoxin requires Biosafety Level 3 (BSL-3) laboratories to mitigate aerosol transmission risks, with enhanced security measures for Tier 1 select toxins, including background checks, inventory controls, and incident reporting to prevent unauthorized access or theft.^[133] These regulations limit production to registered facilities, ensuring that only authorized entities can cultivate C. botulinum or purify the toxin.^[132] Recent structural studies in 2025, including cryo-EM analyses of botulinum neurotoxin serotype A activation mechanisms and the full 14-subunit complex of serotype B, have elucidated key proteolytic and assembly processes, facilitating safer recombinant production in non-pathogenic hosts like E. coli by enabling targeted engineering to avoid full toxicity during manufacturing.^[134]^[14] These insights build on the toxin's core structure—a di-chain protein with light and heavy chains linked by a disulfide bond—to support scalable, controlled synthesis for therapeutic applications.^[134]

Ongoing Research

Neurological and Psychiatric Applications

Botulinum toxin has emerged as a promising investigational treatment for major depressive disorder, particularly in cases resistant to conventional therapies. The 2024 OnaDEP randomized controlled trial evaluated onabotulinumtoxinA injections into the glabella muscles, demonstrating significant reductions in depressive symptoms as measured by the Hamilton Depression Rating Scale, with effects attributed to the facial feedback hypothesis—wherein paralyzing frown muscles disrupts negative emotional feedback loops to the brain.^[135] This hypothesis posits that facial expressions influence emotional states, and interrupting frowning may alleviate mood disturbances. Meta-analyses of randomized controlled trials have corroborated these findings, reporting response rates of 40-60% for botulinum toxin type A compared to placebo, with greater efficacy observed in women and at higher doses.^[136] These results suggest potential as an adjunctive therapy, though optimal dosing and injection sites require further refinement. In the realm of sexual dysfunction with neurological underpinnings, botulinum toxin has been explored for premature ejaculation through phase II clinical trials initiated in 2013. These studies, including dose-escalation assessments of onabotulinumtoxinA injected into perineal muscles such as the bulbospongiosus, have shown preliminary results where doses around 75 units increased intravaginal ejaculatory latency time (IELT) by 3-6 times in affected men in some trials, potentially by inhibiting hyperactive muscle contractions during the ejaculatory reflex.^[137] For instance, one prospective trial reported IELT rising from a baseline of approximately 44 seconds to 141 seconds at four weeks post-injection, alongside improvements in patient-reported satisfaction, though effects waned after 3-6 months necessitating repeat dosing.^[138] However, a 2025 meta-analysis of randomized controlled trials concluded that botulinum toxin-A is ineffective for premature ejaculation treatment.^[139] Adverse events were mild, primarily localized pain, but long-term safety data remain sparse. For upper motor neuron disorders, ongoing research examines botulinum toxin's role in managing post-stroke spasticity and sialorrhea associated with conditions like amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Post-stroke trials have investigated targeted injections to reduce limb spasticity, showing sustained improvements in muscle tone and function for up to 12 weeks, which may enhance rehabilitation outcomes beyond standard approved indications. In sialorrhea, phase III trials such as the OPTIMYST study, completed in 2025, demonstrated that rimabotulinumtoxinB injections into salivary glands significantly decreased saliva production in patients with chronic sialorrhea, including those with ALS and Parkinson's, with response rates exceeding 70% and minimal systemic side effects.^[140] IncobotulinumtoxinA has also shown efficacy in separate studies for sialorrhea in these populations. These findings highlight botulinum toxin's utility in alleviating burdensome symptoms that impair quality of life in neurodegenerative contexts. Despite these advances, evidence gaps persist in neurological and psychiatric applications of botulinum toxin. Long-term data on psychiatric outcomes, including durability beyond 6-12 months and risks of tolerance or antibody formation, are limited, with most studies focusing on short-term efficacy.^[141] Recent reviews, including those from 2025, emphasize the need for larger, multicenter randomized controlled trials to establish standardized protocols and address heterogeneity in patient populations.^[141] Additionally, challenges such as stigma surrounding mental health interventions may impede widespread adoption, as patients and clinicians grapple with perceptions of botulinum toxin as a "cosmetic" rather than therapeutic agent for psychiatric conditions.^[142] These barriers underscore the importance of education and interdisciplinary collaboration to integrate botulinum toxin into broader neurological care frameworks.

Novel Delivery and Formulations

Recent advancements in recombinant botulinum toxin engineering focus on modifying the protein structure to enhance specificity and minimize immunogenicity. Researchers have developed variants of botulinum neurotoxin type A (BoNT/A) by incorporating mutations in the receptor-binding domain, translocation domain, and enzymatic cleft to reduce toxicity while preserving therapeutic efficacy.^[143] For instance, functional deimmunization techniques have produced light chain (LC) variants with altered epitopes, demonstrating reduced antibody formation in humanized mouse models and maintained paralytic activity in vivo.^[144] These recombinant forms, often limited to the LC to avoid full holotoxin immunogenicity, aim to extend treatment intervals by lowering the risk of neutralizing antibodies in repeated administrations.^[145] Innovative delivery methods are expanding beyond traditional intramuscular injections to improve patient compliance and precision. Microneedle arrays have shown promise for transdermal delivery of BoNT/A, enabling painless penetration into the dermis for cosmetic and hyperhidrosis applications; studies report effective sebum reduction and skin barrier enhancement with minimal side effects.^[146] Topical formulations, such as nanoemulsion-based creams, facilitate non-invasive absorption through the skin, with clinical trials demonstrating sustained neuromodulation for glabellar lines and axillary hyperhidrosis.^[147] Additionally, gene therapy vectors like adeno-associated viruses (AAV) have been explored to deliver BoNT LC genes for sustained intracellular expression, potentially providing long-term release in neuronal targets without repeated dosing.^[148] New formulations emphasize extended duration and ease of use. DaxibotulinumtoxinA (Daxxify, formerly RT002), a peptide-stabilized BoNT/A, achieved median response durations of 24 weeks in phase 3 trials for glabellar lines, offering 5-7 months of effect compared to 3-4 months for standard onabotulinumtoxinA.^[149] RelabotulinumtoxinA, a ready-to-use liquid formulation, exhibits higher enzymatic activity and rapid onset, with phase 3 data confirming 6-month efficacy in cosmetic indications and improved stability over reconstituted products.^[150] Ongoing research in 2024-2025 includes trials for alternative routes to treat systemic conditions. Phase 1 studies on intranasal BoNT/A spray for rhinitis report safety and symptom reduction without systemic spread, potentially broadening access for upper airway disorders.^[151] Nanotechnology-based encapsulation, using liposomes or polymeric nanoparticles, enhances stability and targeted release; for example, phosphatidylcholine/cholesterol nanoliposomes enable transdermal BoNT/A delivery with controlled kinetics, reducing off-target effects.^[152] These innovations collectively address safety concerns by minimizing diffusion risks through localized delivery. Non-injectable approaches like microneedles and topicals for hyperhidrosis limit unintended muscle weakening, with preclinical data showing precise dermal confinement and lower adverse event rates.^[153]

References

[1]
Botulinum Toxin - StatPearls - NCBI Bookshelf
Nov 6, 2023 · Botulinum toxin is a medication used to manage and treat therapeutic and cosmetic purposes. Medicinal uses include chronic migraine, spastic disorders, ...
[2]
About Botulism - CDC
Apr 18, 2024 · Botulism is a rare but serious illness. · It is caused by a toxin that attacks the body's nerves and causes difficulty breathing, muscle ...
[3]
BOTULINUM TOXIN - PMC - NIH
Botulinum toxin, one of the most poisonous biological substances known, is a neurotoxin produced by the bacterium Clostridium botulinum.
[4]
Clostridium botulinum - an overview | ScienceDirect Topics
Clostridium botulinum is a gram-positive, rod-shaped, strictly anaerobic spore-former that produces oval endospores commonly found in soil, freshwaters, and ...
[5]
Historical notes on botulism, Clostridium botulinum ... - PubMed
... discovery of the pathogen Clostridium botulinum by Emile Pierre van Ermengem, Professor of bacteriology at the University of Ghent. The bacterium was so ...
[6]
Clostridium botulinum: Infectious substances pathogen safety data ...
Sep 25, 2024 · C. botulinum are Gram-positive, anaerobic, rod-shaped, spore-forming bacilli that may occur singly, in pairs, or in chains and vary in size.Missing: habitat | Show results with:habitat
[7]
Clostridium botulinum - an overview | ScienceDirect Topics
Clostridium botulinum is a spore forming, obligate anaerobe whose natural habitat is soil, from which it can be isolated without difficulty. The toxin exists ...
[8]
Botulism - World Health Organization (WHO)
Sep 25, 2023 · Spores produced by the bacteria Clostridium botulinum are heat-resistant and exist widely in the environment, and in the absence of oxygen they ...Missing: habitat serotypes discovery
[9]
https://listlabs.com/botulinum-producing-bacteria/
[10]
Preventing Foodborne Illness: Clostridium botulinum
Apr 28, 2025 · These endospores, which are very resistant to a number of environmental stresses, such as heat and high acid, can become activated in anaerobic ...
[11]
Molecular Structure of the 900 Kd Botulinum Neurotoxin Complex
Botulinum neurotoxin complex serotype A is a 900 kiloDalton (kDa) protein produced as one of eight serotypes (A-G) by the anaerobic bacterium Clostridium ...
[12]
Emerging Opportunities for Serotypes of Botulinum Neurotoxins - PMC
BoNT/A is the most potent serotype and has the longer acting proteolytic activity. Botulinum neurotoxin duration was estimated according its proteolytic ...
[13]
Structure of the complete 14-subunit botulinum neurotoxin B ...
Aug 27, 2025 · Botulinum neurotoxin serotype B1 (BoNT/B) is a highly potent neurotoxin and therapeutic agent. Here, we present the structure of the ...
[14]
Historical Perspectives and Guidelines for Botulinum Neurotoxin ...
Sequencing has confirmed the distinctiveness of the seven botulinum neurotoxin serotypes (types A–G), with amino acid differences between the seven neurotoxin ...
[15]
A molecular basis underlying differences in the toxicity of botulinum ...
The severity and duration of BoNT intoxication vary widely among the seven known serotypes, labelled A–G in accordance with the chronological order of their ...Missing: antigenicity | Show results with:antigenicity<|separator|>
[16]
The Zinc-Dependent Protease Activity of the Botulinum Neurotoxins
The heavy chain (HC, ~100 kDa) has three structurally dissimilar domains. The so-called C-fragment is composed of two all-b domains (HCC and HCN, ~50 kDa; ...
[17]
Structural characterisation of the catalytic domain of botulinum ...
Mar 14, 2018 · BoNTs consist of a light chain (LC, ~50 kDa) and a heavy chain (HC, ~100 kDa) linked by an inter-chain disulphide bridge. LC is a zinc-dependent ...
[18]
HEAT INACTIVATION RATES OF BOTULINUM TOXINS A, B, E AND ...
Twenty minutes at 79°C or 5 min at 85°C is recommended as the minimum heat treatment for inactivation of 10 3 LD 50 botulinum toxins per gram of the foods ...
[19]
Tables of Toxicity of Botulinum and Tetanus Neurotoxins - MDPI
The toxicity of BoNT/A1 L-PTC in humans was estimated by extrapolation from primate studies to be 1 µg/kg of body weight when taken orally, 10 ng/kg by ...2. Botulinum Neurotoxins · 2.3. Oral Toxicity In Mice · 3. Tetanus Neurotoxin<|control11|><|separator|>
[20]
https://www.mdpi.com/2072-6651/11/12/686
[21]
https://doi.org/10.1124/pr.116.012658
[22]
https://doi.org/10.1073/pnas.0609713104
[23]
Botulinum Neurotoxins in Central Nervous System: An Overview ...
Botulinum neurotoxins (BoNTs) are potent inhibitors of synaptic vesicle fusion and transmitter release. The natural target of BoNTs is the peripheral ...
[24]
https://pmc.ncbi.nlm.nih.gov/articles/PMC11766063/
[25]
The whole truth about botulinum toxin – a review - PMC
Injections with botulinum toxin are effective for many clinical disorders that involve involuntary muscle activity or increased muscle tone.
[26]
https://pmc.ncbi.nlm.nih.gov/articles/PMC7874868/
[27]
Uses of botulinum toxin injection in medicine today - PMC - NIH
Very small amounts of botulinum toxin can lead to botulism, a descending paralysis with prominent bulbar symptoms and often affecting the autonomic nervous ...
[28]
Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021
May 7, 2021 · Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
[29]
Botulism - StatPearls - NCBI Bookshelf - NIH
Botulism is a rare but life-threatening neuroparalytic syndrome caused by the botulinum neurotoxin, most often produced by the bacterium Clostridium botulinum.
[30]
National Botulism Surveillance Summary, 2021 - CDC
May 21, 2025 · In 2021, health departments reported 273 cases of botulism to CDC. Of those, 243 cases were laboratory-confirmed and 30 were probable.Infant Botulism Cases · Wound Botulism Cases · Foodborne Botulism Cases
[31]
Clinical Overview of Botulism - CDC
Apr 22, 2024 · Botulism is a neuroparalytic illness characterized by symmetric, descending flaccid paralysis of motor and autonomic nerves, always beginning with the cranial ...
[32]
Laboratory Diagnostics of Botulism - PMC - NIH
Typical clinical symptoms of all forms of botulism include cranial muscle paralysis, such as double vision and dilated pupils, slurred speech, dry mouth, ...Missing: prognosis | Show results with:prognosis<|control11|><|separator|>
[33]
Treatment of Botulism - CDC
Apr 17, 2024 · Botulism is treated with antitoxin, which prevents the toxin from causing any more harm. Antitoxin does not heal the damage the toxin has already done.
[34]
[PDF] Botox - accessdata.fda.gov
Initial U.S. Approval: 1989 ... BOTOX is indicated for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential.
[35]
Botulinum Toxin for the Upper Limb After Stroke (BoTULS) Trial
Botulinum toxin is increasingly used to treat spasticity due to stroke. Treatment has been shown to reduce muscle tone and improve basic upper limb activities ...
[36]
Botulinum toxin type A therapy for cervical dystonia - Rodrigues, FB
Nov 12, 2020 · The results show that a single treatment session improved cervical dystonia symptoms, including pain, and participant's self‐evaluations.
[37]
Evidence-based systematic review on the efficacy and safety of ...
Results: Overall analysis showed clinical improvement between baseline and 4-6 weeks after application of BoNTA of the patient's spasticity score using the MAS ...
[38]
AAPM&R consensus guidance on spasticity assessment and ...
May 21, 2024 · INJ-1: The AAPM&R Spasticity TEP recommends clinicians consider use of botulinum toxin A for management of focal upper and lower limb spasticity ...
[39]
[PDF] bla stn 103000/5215 - fda approved labeling text
Important limitations: . Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month).
[40]
FDA Approves Botulinum A Toxin for Severe Chronic Migraine - LWW
Nov 4, 2010 · The US FDA has approved prophylactic injections of botulinum A (Botox) for patients who suffer chronic migraines lasting for four hours or more ...Article In Brief · Basis For Approval · Approval Welcomed
[41]
OnabotulinumtoxinA for treatment of chronic migraine
The PREEMPT 1 study was conducted from January 23, 2006, to July 16, 2008, at 56 North American sites. PREEMPT 1 was conducted to evaluate the ...
[42]
OnabotulinumtoxinA for treatment of chronic migraine - PubMed
The pooled PREEMPT results demonstrate that onabotulinumtoxinA is an effective prophylactic treatment for chronic migraine.Missing: original | Show results with:original
[43]
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled ...
Jun 1, 2010 · A pooled analysis of these 2 Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) studies was performed to examine the durability ...Missing: original paper
[44]
Mechanisms of Botulinum Toxin Type A Action on Pain - MDPI
Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over ... "Mechanisms of Botulinum Toxin Type A Action on Pain" Toxins 11, no. 8: 459 ...
[45]
Botulinum Neurotoxin for the Treatment of Neuropathic Pain - Frontiers
Botulinum neurotoxin is widely used for central and peripherical neurological conditions. Initially used to treat muscle spasticity, over the years its use ...
[46]
Botulinum Toxin for the Treatment of Neuropathic Pain - MDPI
Recent studies have demonstrated that BoNT injections are effective treatments for post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, and ...
[47]
Botulinum toxin as an effective rescue treatment after failure of anti ...
Oct 1, 2025 · In our population, BoNT/A proved helpful in chronic migraineurs who did not benefit from anti-CGRP antibodies, probably by bypassing a purely ...
[48]
Comparing eptinezumab with onabotulinumtoxinA in the treatment ...
Jul 14, 2025 · Forty chronic migraine patients refractory to standard treatments were observed, of which 15 were over 50 years old, and 4 exceeded 65 years. ...
[49]
[PDF] BOTOX® (Botulinum Toxin Type A) - accessdata.fda.gov
BOTOX® is indicated for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical ...
[50]
The effectiveness and safety of botulinum toxin injections for the ...
Oct 12, 2023 · Compared with a placebo, BoNT significantly reduced the DSFS of sialorrhea in PD patients. The recommended evidence level is high in terms of ...
[51]
Botulinum toxin in spinal cord injury patients with neurogenic ... - NIH
Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity ... In late August 2011, Botox received U.S. FDA approval for ...
[52]
Treatment of neurogenic detrusor overactivity and... - LWW
Jul 1, 2023 · Long-term studies in NDO and OAB showed sustained effectiveness and safety with repeat injections of onabotulinumtoxinA, the use of which has ...
[53]
Botulinum toxin injection for facial wrinkles - PubMed
Aug 1, 2014 · Injection of small quantities of botulinum toxin into specific overactive muscles causes localized muscle relaxation that smooths the overlying ...Missing: mimetic | Show results with:mimetic
[54]
Botulinum Toxin Type A - Product Approval Information - Licensing ...
Under this approval, Botulinum Toxin Type A (BOTOX COSMETIC) may be used for the temporary improvement in the appearance of moderate to severe glabellar lines ...
[55]
[PDF] 4161688 This label may not be the latest approved by FDA. For ...
Forehead Lines. In the two forehead lines clinical studies of BOTOX Cosmetic, the responder rates appeared to be higher for subjects younger than age. 65 than ...
[56]
[PDF] BLA 103000/S-5303 SUPPLEMENT APPROVAL Allergan, Inc.
temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity. APPROVAL & LABELING. We have ...
[57]
[PDF] HIGHLIGHTS OF PRESCRIBING INFORMATION - RxAbbVie
The duration of effect of BOTOX Cosmetic for glabellar lines is approximately 3-4 months.
[58]
Drug Trials Snapshots: LETYBO - FDA
Mar 22, 2024 · Approval date: February 29, 2024 ... LETYBO is a drug used in adults to temporarily improve the appearance of moderate to severe glabellar lines ( ...
[59]
[PDF] Reference ID: 5337801 - accessdata.fda.gov
LETYBO is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle ...
[60]
[PDF] 2023 Plastic Surgery Statistics Report
Sep 26, 2023 · In 2023, there were 4,715,716 pro- cedures of using botulinum toxin type A (including. Botox®, Dysport® and Xeomin®), reflecting a 6 per- cent ...
[61]
An Update on the Cosmetic Use of Botulinum Toxin - MDPI
May 4, 2022 · Masseter hypertrophy was the most popular indication (48.9%), followed by cobblestone chin (25.9%), smoker's lines (18.8%), and platysmal band ( ...
[62]
[PDF] Botox Label - accessdata.fda.gov
BOTOX is indicated for the treatment of upper limb spasticity in adult patients, to decrease the severity of increased muscle tone in elbow flexors (biceps), ...<|control11|><|separator|>
[63]
Dose-Effect Relationship of Botulinum Toxin Type A in the ... - NIH
Oct 11, 2024 · The dosage for strabismus treatment ranges from 1.25 to 25 units (0.05 and 0.15 mL) per muscle per session. It could be given in one or more ...
[64]
Botulinum Toxin Use In Strabismus - EyeWiki
... approved on December 29, 1989 by the Food and Drug Administration (FDA) and the National Eye Institute (NEI) for the treatment of strabismus and blepharospasm.
[65]
Review of the FDA-approved uses of botulinum toxins ... - PubMed
Studies conducted in patients with cervical dystonia have shown that botulinum toxin effectively reduces pain associated with this disorder.
[66]
Botulinum Toxin for the Treatment of Hemifacial Spasm - NIH
Dec 9, 2021 · Literature review of published articles regarding Botulinum toxin for HFS. ... From the literature, the efficacy of BONT ranged from 73% to 98.4%.
[67]
Botulinum toxin type A therapy for hemifacial spasm - Duarte, GS
Nov 19, 2020 · We reviewed the evidence about the effect of botulinum toxin type A (BtA) in people with one‐sided, involuntary contractions of facial ...
[68]
Pharmacotherapy for the management of achalasia: Current status ...
This article reviews currently available pharmacological options available for the treatment of achalasia, with a special focus on the role of botulinum toxin ( ...
[69]
Intrasphincteric Botulinum Toxin for the Treatment of Achalasia
Mar 23, 1995 · Injection of botulinum toxin into the lower esophageal sphincter is an effective, safe, and simple method of treatment for achalasia, with results that are ...
[70]
Treatment of achalasia: the short-term response to botulinum toxin ...
It has been suggested that intrasphincteric injection of botulinum toxin (BTX) may represent an alternative therapy to balloon dilatation in achalasia.
[71]
Treatment of pediatric spasticity, including children with cerebral ...
Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015;7:1629–48. [DOI] [PMC free article] [PubMed] ...
[72]
[PDF] Clinical Review (Botox) - FDA
Oct 18, 2019 · Dysport (abobotulinumtoxinA) received Orphan Designation for the treatment of pediatric lower limb (LL) spasticity secondary to cerebral palsy ...<|separator|>
[73]
[PDF] BOTOX (onabotulinumtoxinA) Label - accessdata.fda.gov
Safety and effectiveness of BOTOX have not been established for the treatment of spasticity in This label may not be the latest approved by FDA. For current ...
[74]
A review on iatrogenic botulism - Fung - 2020 - Wiley Online Library
Nov 1, 2020 · Animal studies have shown that botulinum toxin can spread to a distance of 30–45 mm from the injection site. Distant effects may be attributed ...
[75]
Immunogenicity of Botulinum Toxin Type A in Different Clinical ... - NIH
The incidence of neutralizing antibody formation varied across indications, ranging from 2.1% in cervical dystonia to 26.7% in blepharospasm. The incidence of ...
[76]
Immunogenicity Associated with Botulinum Toxin Treatment - PMC
Aug 26, 2019 · BoNT-A is generally 95% activated during manufacturing, but approximately 25–30% of BoNT-B remains inactive, which may contribute to its ...
[77]
Cervical Dystonia | BOTOX ONE® | BOTOX® (onabotulinumtoxinA)
The most frequently reported adverse reactions following injection of BOTOX for cervical dystonia include dysphagia (19%), upper respiratory infection (12%), ...
[78]
Occurrence of Dysphagia Following Botulinum Toxin Injection in ...
Nov 3, 2016 · Dysphagia is the most common treatment-related adverse effect of BoNT therapy, and is believed to occur as a result of regional spread of the ...Missing: distant | Show results with:distant
[79]
Delayed Hypersensitivity Reaction to OnabotulinumtoxinA - PMC - NIH
Among the more severe reactions, outcomes including circulatory and respiratory compromise and even death7 have occurred.
[80]
[PDF] Iatrogenic botulism after botulinum toxin type A: Five cases
However, in rare cases, iatrogenic botulism may occur when the toxin enters the vascular space.Missing: cardiovascular | Show results with:cardiovascular
[81]
ASDS 2024: new phase III READY-4 data demonstrate long-term ...
Oct 21, 2024 · First results from the phase III READY-4 trial demonstrate the long-term safety of repeated injections of RelabotulinumtoxinA for both frown ...Missing: surveillance | Show results with:surveillance
[82]
[PDF] This label may not be the latest approved by FDA. For current ...
No definitive serious adverse event reports of distant spread of toxin effect associated with BOTOX for blepharospasm at the recommended dose (30 Units and ...
[83]
FDA requires black box warnings on labeling for botulinum toxin ...
FDA requires black box warnings on labeling for botulinum toxin products. JAMA. 2009 Jun 10;301(22):2316. doi: 10.1001/jama.2009.780.
[84]
The Botulism Outbreak That Gave Rise to America's Food Safety ...
Aug 3, 2018 · In late 1919 and early 1920, scientists and canners worked with the government to protect the public from the deadly toxin.Missing: development | Show results with:development
[85]
Food Safety Objective Approach for Controlling Clostridium ...
Nov 1, 2011 · The application of the “botulinum cook” is defined as equivalent to 3 minutes heating at 121°C. This value is also the Fo value or the process ...
[86]
Studies on Botulinus Toxin: 2. Further Purification by Adsorption on ...
H. Sommer, P. Tessmer Snipe; Studies on Botulinus Toxin: 2. Further Purification by Adsorption on Colloids, The Journal of Infectious Diseases, Volume 43,
[87]
Botulinum Toxin in WW2 German and Allied Armies
Jan 20, 2021 · The outbreak of WW2 was the beginning of a new period of military research on botulinum toxin, leading to a succession of failures and myths ...Missing: UK | Show results with:UK
[88]
The Spoils of War: Exploiting the German and Japanese Research ...
Dec 12, 2024 · In other studies, humans were placed in gas chambers and exposed to toxic pathogens. Japanese researchers fed botulinum toxin to prisoners of ...
[89]
The Action of Botulinum Toxin on the Neuro-Muscular Junction
The Action of Botulinum Toxin on the Neuro-Muscular Junction. J Physiol. 1949 Aug;109(1-2):10-24. doi: 10.1113/jphysiol.1949.sp004364. Authors. A S V BURGEN ...Missing: Arnold blockade vitro
[90]
Ed Schantz, 96; Helped Purify Toxin Used in Botox Injections
May 5, 2005 · In 1946, Schantz and colleagues purified botulinum toxin type A -- the poison that causes an often fatal form of muscle paralysis called ...Missing: 1950s- | Show results with:1950s-
[91]
A History of Biological Weapons | American Experience - PBS
... destruction.” Although Nixon's initial statement does not mention toxins such as botulinum toxin, on February 14, 1970, he will makes clear that those ...Missing: stockpile LD50
[92]
Botulinum toxin: Bioweapon & magic drug - PMC - NIH
The lethal dose for a person by the oral route is estimated at 30 ng69, by the inhalational route 0.80 to 0.90 µg, and by the intravenous route 0.09 to 0.15 µg ...
[93]
Search Orphan Drug Designations and Approvals - FDA
Marketing approved: ; Botox · 12/29/1989 · Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above) · 12/29/1996.
[94]
[PDF] Botulinum Toxin Type A (Botox), Allergan, Inc. Approval Letter
Under this approval, BOTOX is indicated for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain ...
[95]
[PDF] BLA 103000 S-5215 - accessdata.fda.gov
This “Prior Approval” efficacy supplement to your BLA provides for a new indication for the prophylaxis of headaches in adults with chronic ...
[96]
Allergan Agrees to Plead Guilty and Pay $600 Million to Resolve ...
Sep 1, 2010 · The civil settlement addresses allegations that from 2001 through at least 2008, Allergan promoted Botox for off-label indications that were not ...Missing: boom trademark
[97]
[PDF] DYSPORT™ for Injection - accessdata.fda.gov
Infection at the proposed injection site. FDA APPROVED LABELING 4/29/09. This label may not be the latest approved by FDA. For current labeling information, ...Missing: EU | Show results with:EU
[98]
[PDF] BLA 125360 Xeomin Label - accessdata.fda.gov
See full prescribing information for. XEOMIN. XEOMIN (incobotulinumtoxinA) for injection, intramuscular use. Initial U.S. Approval: 2010. WARNING: Distant ...
[99]
[PDF] JEUVEAU (prabotulinumtoxinA-xvfs) for injection, for intramuscular ...
Initial U.S. Approval: 2019. WARNING: DISTANT SPREAD OF TOXIN. EFFECT. See full ... JEUVEAU is not approved for the treatment of spasticity or any ...
[100]
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Feb 2, 2024 · Global Botox Cosmetic net revenues were $718 million , an increase of 11.8 percent on a reported basis, or 12.3 percent on an operational basis.
[101]
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for ...
Jul 9, 2020 · First approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults, BOTOX® was the world's first ...
[102]
[PDF] Controlled Substances - Alphabetical Order
... Schedule, "CSCN" = Controlled Substance Code Number. Controlled Substances - Alphabetical Order. 15-Oct-25. Page 2 of 22. Page 3. SUBSTANCE. 2,5-Dimethoxy-4-(n ...Missing: Botulinum toxin
[103]
OnabotulinumtoxinA Use During Pregnancy - Drugs.com
Advice and warnings for the use of OnabotulinumtoxinA during pregnancy. FDA Pregnancy Category C - Risk cannot be ruled out.
[104]
[PDF] Botox REMS - accessdata.fda.gov
Botulinum Toxin Type A. Allergan, Inc. 2525 Dupont Drive. Irvine, CA 92612. Tel 714-246-5327. RISK EVALUATION AND MITIGATION STRATEGY (REMS). I. GOAL(S). The ...
[105]
Botox - referral | European Medicines Agency (EMA)
Botox [Clostridium botulinum toxin type A neurotoxin complex] inhibits the release of acetylcholine at the presynaptic membrane on cholinergic neurons.
[106]
[PDF] tertiary and quaternary level essential medicines list
Jul 29, 2021 · M03AX01. Botulinum toxin. Focal dystonias. Approved for use in carefully selected patients. Only to be administered by suitably experienced ...
[107]
Budget impact analysis of botulinum toxin type A for patients with sev
Oct 11, 2025 · However, its high cost poses a barrier to access within Thailand's healthcare system. This study aimed to assess the budget impact of ...Missing: income | Show results with:income
[108]
Off Label Botox Use: Where Do We Stand in 2025 - MEDICA DEPOT
Jan 27, 2025 · Aesthetic Innovations: Off-label treatments like masseter reduction, gummy smile correction, and neck rejuvenation have gained popularity, ...
[109]
Botox Insurance Help - International Hyperhidrosis Society
Botox Savings Program: Through this program, eligible axillary (underarm) hyperhidrosis patients can save on out-of-pocket costs related to Botox medicine and ...Missing: cosmetic | Show results with:cosmetic
[110]
https://news.abbvie.com/2020-07-09-FDA-Approves-Expanded-BOTOX-R-onabotulinumtoxinA-Label-for-the-Treatment-of-Pediatric-Patients-with-Spasticity
[111]
FDA Smooths Way For Botox - Forbes
Apr 16, 2002 · Allergan, which specializes in eye care, said it will now begin marketing the product as Botox Cosmetic to doctors and directly to consumers.
[112]
Adverse Reactions Linked to Botox - U.S. Pharmacist
Mar 20, 2008 · The adverse reactions may include difficulty swallowing, weakness, and breathing problems. Following a review of data from clinical studies and ...Missing: recall | Show results with:recall
[113]
EP2276851A1 - Method of producing clostridium botulinum toxin ...
... botulinum toxin could be effectively produced by using a disposable bioreactor through fermentation that used strict anaerobes, Clostridium botulinum strains.Missing: mg/ | Show results with:mg/
[114]
(PDF) Production and Purification of Clostridium botulinum ...
Mar 6, 2025 · Hall A yielded maximum toxin activity (1 × 10⁷ mouse LD₅₀ units/mL) after 5 days of anaerobic incubation. Purification achieved approximately 1, ...Missing: fermentation bioreactors
[115]
Simplified purification method for Clostridium botulinum type E toxin
At least 1.5 mg of pure toxin was obtained from each liter of culture, and the toxicity was 6 X 10(7) 50% lethal doses per mg of protein. These values are ...Missing: production fermentation anaerobic bioreactors yield
[116]
Complexing proteins in botulinum toxin type A drugs - NIH
Complexing proteins don't affect neurotoxin diffusion or stability, but may stimulate antibody development, potentially causing therapy failure.Missing: AG | Show results with:AG
[117]
Complexing Protein-Free Botulinum Neurotoxin A Formulations
Feb 10, 2024 · All three BoNT/A formulations are free of complexing proteins and contain the core BoNT/A molecule as the active pharmaceutical ingredient.Missing: serotype naked
[118]
Recognition of Illness Associated with the Intentional Release ... - CDC
Sep 11, 2001 · Agents of highest concern are Bacillus anthracis (anthrax), Yersinia pestis (plague), variola major (smallpox), Clostridium botulinum toxin ...Missing: dual- | Show results with:dual-
[119]
Biosecurity Threat Posed by Botulinum Toxin - PMC - PubMed Central
Nov 20, 2019 · Botulinum neurotoxin (BoNT) is one such biological threat, characterized by an extremely low lethal dose, high morbidity and mortality when appropriately ...Missing: anthrax | Show results with:anthrax
[120]
History - Federal Select Agent Program
In October 2001, bioterrorism in the US became a reality again when four letters laced with anthrax were sent through the US Postal Service.Missing: Botulinum Category dual- concerns
[121]
Bioterrorism and the Role of the Clinical Microbiology Laboratory
Dec 9, 2015 · The tier 1 select agents are as follows: botulinum neurotoxins, botulinum neurotoxin-producing species of Clostridium, Ebola virus, Francisella ...
[122]
Elucidating the activation mechanism of botulinum neurotoxin a
Oct 24, 2025 · Additionally, the mechanism of BoNT/A activation can be harnessed to produce active recombinant BoNT/A for therapeutic and cosmetic applications ...
[123]
A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP ...
Sep 12, 2024 · Background: OnabotulinumtoxinA (OnaA) injection in glabella area appears to be a promising treatment for major depression.
[124]
Botulinum Neurotoxin Therapy for Depression - Frontiers
The response rates of BoNT/A and placebo groups were 60.0 and 13.3%, respectively. This trial suggested that a single injection of BoNT/A in the glabellar ...
[125]
A Safety and Efficacy Study of OnabotulinumtoxinA in Premature ...
This is a safety and efficacy study of OnabotulinumtoxinA for the treatment of premature ejaculation (PE) in male participants.Missing: 75 units
[126]
Clinical Efficacy and Safety of Botulinum Toxin A Injection into the ...
Mar 28, 2025 · At the 4-week follow-up, the IELT in patients with lifelong PE significantly increased from 44.4 ± 16.2 s at baseline to 141 ± 109.8 s (p = .000) ...
[127]
Results of the OPTIMYST Trial | Neurology and Therapy
Jun 11, 2025 · In this phase 3, open-label multicenter study, 187 adult participants with troublesome sialorrhea due to Parkinson disease (65.8%), amyotrophic ...
[128]
An Unconventional Tool for the Treatment of Depression? - PubMed
Sep 10, 2025 · This narrative review critically examines the current preclinical and clinical findings of BoNT-A in MDD. Methods: A comprehensive search of ...
[129]
Mental health and quality of life in patients with craniofacial ... - NIH
Sep 21, 2022 · First, this was a cross-sectional study that failed to compare changes in stigma after treatment with botulinum toxin. Second, since there ...
[130]
Potency Evaluations of Recombinant Botulinum Neurotoxin A1 ...
Aug 17, 2024 · In this study, we added four additional mutations in the receptor-binding domain, translocation domain, and enzymatic cleft to further decrease toxicity.
[131]
Functional Deimmunization of Botulinum Neurotoxin Protease ...
Jan 9, 2023 · Many of these variants exhibited decreased immunogenicity in humanized HLA transgenic mice and manifested in vivo paralytic activity when ...
[132]
Immunogenicity of Botulinum Toxin Formulations: Potential ... - NIH
Sep 13, 2021 · Immunogenicity after long-term treatment with BoNT formulations may occur, and repeated use can elicit antibody formation leading to clinical nonresponsiveness.
[133]
Microneedle delivery of botulinum toxin type A combined ... - PubMed
Conclusions: Microneedle delivery of BTX-A/HA decreases sebum production while improving skin barrier function. Thus, this combined therapy can relieve the side ...
[134]
Transdermal Delivery of Botulinum Neurotoxin A - MDPI
The aim of this study was to develop a nanoemulsion-based transdermal formulation capable of delivering active botulinum neurotoxin (BoNT) through human skin.
[135]
Adeno-Associated Virus Transfer of a Gene Encoding SNAP-25 ...
AAV vectors provide an efficient and relatively safe way to ensure prolonged expression of genes in neurons (Burger et al., 2005), and botulism in rats ...
[136]
DaxibotulinumtoxinA for Injection has a prolonged duration of ...
Nov 29, 2019 · DAXI offers a prolonged duration of response for glabellar line reduction and is well tolerated.
[137]
RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator ...
Oct 9, 2025 · RelabotulinumtoxinA contained more BoNT-A1 per on-label GL dose (0.27 ng) than onabotulinumtoxinA (0.18 ng), had higher enzyme activity (53 vs.
[138]
https://pmc.ncbi.nlm.nih.gov/articles/PMC11954517/
[139]
Transdermal delivery of botulinum toxin-A through ...
Jul 29, 2024 · Transdermal delivery of botulinum toxin-A (BTXA) is a promising strategy for PAS treatment, but currently reported approaches are far from satisfactory.<|separator|>
[140]
Microneedling Delivery of Botulinum Toxin Versus Intradermal ...
Both techniques were safe and effective in controlling the FH. Microneedling delivery of BTX-A was less painful and had higher patient satisfaction.